Ingredient
Perfluoroisohexane
Perfluoroisohexane is flagged for pregnancy, breastfeeding, trying to conceive, postpartum, PCOS and general use. The concern behind the strongest flag is absorbed into the body and fetal development.
- Perfluoro-isohexane
- F-isohexane
Verdict by profile
Truva checks every ingredient against six profiles. Jump to any of them for the full assessment.
- Strongest verdict
- Not Recommended
- Its verdict for pregnancy, the profile this one is worst in
- Profiles flagged
- 6 of 6
- Counting avoid, high risk and medium risk
- Last checked
- 15 September 2026
- The day this assessment was read from the catalogue
Perfluoroisohexane and pregnancy
Not Recommended
- Absorbed into the body
- Fetal development
Perfluoroisohexane is a perfluorinated compound used as a solvent and spreading agent in cosmetics. It belongs to the PFC family, which includes substances known for their environmental persistence and bioaccumulation potential. While specific pregnancy studies on perfluoroisohexane are lacking, research on related perfluorinated compounds has documented placental transfer and associations with reduced birth weight and developmental concerns. These compounds are fat-soluble and can accumulate in maternal tissues, potentially exposing the developing fetus. The persistent nature of PFCs means they remain in the body for extended periods. Given the concerns about bioaccumulation and the structural similarity to PFCs with documented reproductive effects, most toxicologists recommend avoiding perfluorinated compounds during pregnancy when safer alternatives exist. The lack of specific safety data combined with known concerns about related compounds warrants a precautionary approach.
Perfluoroisohexane and breastfeeding
Not Recommended
- Passes into breast milk
- Infant exposure
Perfluoroisohexane is a fat-soluble perfluorinated compound that can accumulate in body tissues. Research on related PFCs has demonstrated that these compounds can transfer into breast milk due to their lipophilic nature and long half-lives in the body. Studies on other perfluorinated substances have detected measurable levels in breast milk, raising concerns about infant exposure during a critical developmental period. While specific data on perfluoroisohexane transfer is lacking, its chemical structure suggests similar behavior to other PFCs that have been found in maternal milk. Due to the potential for accumulation and transfer to breastfed infants, along with limited safety data, dermatologists typically recommend avoiding perfluorinated compounds while breastfeeding. The precautionary principle applies here given the persistent nature of these chemicals and documented concerns with related compounds.
Perfluoroisohexane and postpartum
Caution Advised
- Absorbed into the body
- Environmental pollutant
For women who are not breastfeeding, the primary concerns with perfluoroisohexane relate to its bioaccumulative properties and environmental persistence rather than immediate reproductive risks. The compound can still accumulate in body tissues over time. While there are no specific contraindications for postpartum women not breastfeeding, the general concerns about PFC accumulation and environmental impact remain. Women may choose to avoid these ingredients as part of a broader strategy to minimize exposure to persistent pollutants, particularly if planning future pregnancies.
Perfluoroisohexane and trying to conceive
Not Recommended
- Builds up in tissue
- Fertility effects
For women trying to conceive, the bioaccumulative nature of perfluoroisohexane is particularly concerning. PFCs can accumulate in body tissues over time, and some research on related compounds has suggested potential associations with reduced fertility and longer time to pregnancy. Because these compounds persist in the body for extended periods, experts generally recommend discontinuing use before attempting conception to minimize body burden. This allows time for existing accumulation to decrease before pregnancy, reducing potential fetal exposure once conception occurs.
Perfluoroisohexane and PCOS
Caution Advised
- Hormone disruptor
Perfluoroisohexane belongs to the perfluorinated compound family, some members of which have shown potential endocrine-disrupting properties in research studies. For women with PCOS, who already experience hormonal imbalances, minimizing exposure to potential endocrine disruptors is often recommended. While specific data on perfluoroisohexane's hormonal effects is limited, the broader category of PFCs has been studied for associations with metabolic and hormonal disruption. Some research suggests links between PFC exposure and insulin resistance, though direct causation remains unclear. Women with PCOS may choose to avoid perfluorinated compounds as a precautionary measure, particularly given the availability of alternative cosmetic ingredients that serve similar functions without the potential hormonal concerns.
Perfluoroisohexane and general use
Caution Advised
- Absorbed into the body
- Environmental pollutant
- Endocrine disruptor
Perfluoroisohexane is a perfluorinated compound used to improve cosmetic texture and spreadability. While it may enhance product performance, it belongs to a chemical class raising increasing environmental and health concerns. The primary issues with PFCs include their extreme persistence in the environment and human body, potential for bioaccumulation, and emerging evidence of endocrine-disrupting properties in some family members. While perfluoroisohexane specifically lacks extensive toxicity data, its structural similarity to problematic PFCs warrants caution. Many consumers and manufacturers are moving away from perfluorinated ingredients due to environmental concerns and the availability of effective alternatives. The EU has begun restricting certain PFCs, and the trend is toward phasing out these persistent chemicals from consumer products.
Everything else flagged for the same profiles
Related ingredients
Ingredients suggested in place of Perfluoroisohexane, each one with its own page here.
Ingredients that raise the same concerns.
Where this came from
Truva summarises published guidance from bodies including ACOG, the FDA, the EU SCCS and the Cosmetic Ingredient Review. It has no access to your medical history and it is not a substitute for your doctor, dermatologist or midwife. These assessments have not been reviewed by a clinician, and nothing here is a diagnosis or a prescription. If you are pregnant, breastfeeding or being treated for PCOS, take the ingredient list to the person looking after you.
Assessment last pulled from the ingredient database on .
One ingredient is the easy case.
A label has thirty of them. Truva reads the whole list at once and answers for the profile you set: pregnancy, breastfeeding, postpartum, trying to conceive, PCOS, or general use.
Download on theApp Store